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Abstract
Background: An approach to molecular classiﬁcation based on the comparative expression of protein pairs is
presented. The method overcomes some of the present limitations in using peptide intensity data for class prediction
for problems such as the detection of a disease, disease prognosis, or for predicting treatment response. Data analysis
is particularly challenging in these situations due to sample size (typically tens) being much smaller than the large
number of peptides (typically thousands). Methods based upon high dimensional statistical models, machine learning
or other complex classiﬁers generate decisions which may be very accurate but can be complex and diﬃcult to
interpret in simple or biologically meaningful terms. A classiﬁcation scheme, called ProtPair, is presented that generates
simple decision rules leading to accurate classiﬁcation which is based on measurement of very few proteins and
requires only relative expression values, providing speciﬁc targeted hypotheses suitable for straightforward validation.
Results: ProtPair has been tested against clinical data from 21 patients following a bone marrow transplant, 13 of
which progress to idiopathic pneumonia syndrome (IPS). The approach combines multiple peptide pairs originating
from the same set of proteins, with each unique peptide pair providing an independent measure of discriminatory
power. The prediction rate of the ProtPair for IPS study as measured by leave-one-out CV is 69.1%, which can be very
beneﬁcial for clinical diagnosis as it may ﬂag patients in need of closer monitoring. The “top ranked” proteins provided
by ProtPair are known to be associated with the biological processes and pathways intimately associated with known
IPS biology based on mouse models.
Conclusions: An approach to biomarker discovery, called ProtPair, is presented. ProtPair is based on the diﬀerential
expression of pairs of peptides and the associated proteins. Using mass spectrometry data from “bottom up”
proteomics methods, functionally related proteins/peptide pairs exhibiting co-ordinated changes expression proﬁle
are discovered, which represent a signature for patients progressing to various disease conditions. The method has
been tested against clinical data from patients progressing to idiopthatic pneumonia syndrome (IPS) following a bone
marrow transplant. The data indicates that patients with improper regulation in the concentration of speciﬁc acute
phase response proteins at the time of bone marrow transplant are highly likely to develop IPS within few weeks. The
results lead to a speciﬁc set of protein pairs that can be eﬃciently veriﬁed by investigating the pairwise abundance
change in independent cohorts using ELISA or targeted mass spectrometry techniques. This generalized classiﬁer can
be extended to other clinical problems in a variety of contexts.
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Background
A biomarker is an indicator of a speciﬁc biological con-
dition, such as presence or progression of a disease, or
treatment response of a drug. Studying protein expression
data to assess utility as potential biomarkers holds special
signiﬁcance since cellular behavior and disease are func-
tions of the abundance and interactions between proteins
involved in biological phenomenon [1]. The expression
of speciﬁc proteins are a function of disease state, prog-
nosis and recovery, and comparative proteomics holds
special promise for revealing such candidates. Tremen-
dous eﬀorts are being made to ﬁnd novel biomarkers in a
wide variety of ﬁelds including cancer research [2], cardio-
vascular disease [3], kidney disease [4], and neurodegen-
erative complications [5]. Reliable proteomics biomarkers
are urgently needed to identify and target the patients
that are likely to progress to a disease for treatment inter-
vention earlier in the course of the disease as well as to
identify patients that are unlikely to progress, and for the
evaluation of therapeutic response. However, progress so
far has been slow.
Mass spectrometry is increasingly used for relative or
absolute quantiﬁcation of peptides and proteins. Tech-
niques such as stable isotope labeling, spectral counting,
and spectral feature analysis have particularly acceler-
ated growth in the ﬁeld of quantitative proteomics [6-
10]. Challenges associated with analyzing data originating
from proteomic biomarker discovery experiments share
similarity with transcriptional proﬁling, such as the inter-
pretation of complex biological samples and the statis-
tical inference associated with high-dimensionality data
sets resulting from a much smaller number of samples
compared to the variable number of analytes [11-13].
Determining the buried structure within such data reli-
ably, such as correlation coeﬃcient or higher-dimensional
patterns, is highly diﬃcult in this limited sample situ-
ation. Given the challenges in computational modeling
with limited sample size and model complexity, some
simplifying assumptions (such as reducing the dimension-
ality of the data or the family of classiﬁers) are typically
made [13]. There is a dilemma associated with some of
the current methods routinely used for proteomics data
analysis since it can be diﬃcult to derive biologically rel-
evant conclusions from the highly complex non-linear
decision boundaries between classes of interest resulting
from some of the standardized pattern recognition tools
such as neural networks [14], decision trees [15], and
support vector machines [16]. Pairwise expression anal-
ysis has been used successfully in the 2 dimesional gel
electrophoresis and mRNA expression proﬁling studies
[17,18]. Using pairs of peptide markers in MS based pro-
teomics studies, as opposed to the single markers used
in traditional analysis, allows for separation to be made
in a 2-dimensional space, allowing for possibly greater
discriminability arising from a greater (twice) amount of
information used in making a decision. Existing evidence
[13,19,20] indicates that simpler classiﬁcation methods
[21] exhibit comparable performance to that of more com-
plex models for such cases. In this study, we investigate
the value of such relatively simple classiﬁcation schemes
in the context of proteomics experiments to extend the
well documented advantages observed for transcriptional
proﬁling classiﬁcation to proteomics biomarker discovery.
Our results support and extend this ﬁnding.
We present a simple comparison-based approach to
classifying protein expression proﬁles, the ProtPair clas-
siﬁer, that ﬁrst diﬀerentiates patients according to pre-
deﬁned clinical variables by ﬁnding pairs of peptides
whose relative expression levels change signiﬁcantly from
one condition to the other. Second, each peptide is then
mapped to its protein identity, and peptide pairs originat-
ing from the same pair of proteins are grouped together to
form protein pairs. Lastly, the resulting protein pairs are
investigated for their ability to consistently diﬀerentiate
between the two clinical states across all possible peptide
pairs, the extent of protein coverage exhibiting the dif-
ferential expression, and consistency in the direction of
change to arrive at the ﬁnal protein pair that leads to the
best classiﬁcation. Multiple peptide pairs originating from
the same pairs of proteins indicating similar patterns of
expression change lead to the top scoring protein pair can-
didates for the clinical problem under consideration. The
method does not rely on data normalization, relies on a
pair of variables that are reproducibly observed, is suit-
able to work with small training data sets, and can provide
biologically meaningful biomarkers.
Rank-based approaches to gene pair selection and
classiﬁcation for classifying gene expression proﬁles
from pairwise mRNA expressions have been success-
fully employed [19,20,22-24]. The full potential of such
methods for proteomics can now be realized as high-
throughput protein comparisons with ascertainment of
thousands of peptides are routine using mass spectrom-
etry based proteomics [25]. Making predictions based
upon relative concentrations of proteins rather than genes
provides a natural and stronger link with biochemi-
cal activity. We hope to realize those beneﬁts towards
characterizing proteomics experiments through modiﬁed
approaches tailored speciﬁcally for such studies. Prot-
Pair generates speciﬁc hypothesis for follow-up studies,
employs few proteins for classiﬁcation and is easy to
interpret. Our approach to selecting informative pairs of
proteins is an attempt to exploit additional information
gained from capturing such joint statistics, with pertur-
bations in pairwise expressions potentially resulting from
protein-protein interactions in extended networks.
The eﬃcacy of ProtPair is demonstrated on a clini-
cal proteomics dataset involving patients progressing to
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Idiopathic Pneumonia Syndrome (IPS) following stem
cell transplantation (SCT) [26,27]. The primary treat-
ment option available for patients diagnosed with cer-
tain malignant and non malignant diseases is allogeneic
hematopoietic SCT. However, success of the procedure
is limited due to a number of complications arising fol-
lowing the intervention. Idiopathic pneumonia syndrome
(IPS) is an occasionally observed alveolar injury following
SCT without the presence of an active lower respiratory
tract infection. Depending upon the bone marrow donor,
IPS can be manifested in 5-15% of patients. IPS typi-
cally begins its onset after about 18 days following the
SCT, with a mortality rate of >70%. Molecular biomark-
ers with even modest predictive power to predict disease
progression would have very high clinical value. Existing
approaches to study IPS lack comprehensiveness as they
target only a few known inﬂammatory proteins, and thus,
are limited with respect to expanding the disease pathway.
In this study, discovery-based, quantitative proteomics is
utilized to provide the identiﬁcation and quantiﬁcation
of hundreds of proteins across global plasma proteome
in an unbiased, comprehensive manner. ProtPair is used
to uncover robust markers that diﬀerentiate patients that
progress to IPS from non-progressors, so that targeted
individualized therapy can be designed for SCT related
complications.
Methods
Blood specimens were obtained at the time of stem cell
transplantation (Day 0). Plasma was separated from the
samples and stored at -80°C until analysis. Aliquots for
individual plasma samples were thawed and depleted of
the seven most abundant proteins. Bovine trypsin was
used for proteolytic digestion. Six hundred nanograms
of each sample were analyzed by liquid chromatography
coupled with mass spectrometry using LTQ-FT as previ-
ously described [28], and the order of sample injections
was randomized over all samples. The chromatograms
across all the spectra thus obtained were time aligned
across multiple runs using Rosetta Elucidator (Rosetta
Biosoftware, Seattle, WA) [29,30]. Proteins were identiﬁed
using Mascot and protein teller within Rosetta Elucidator
framework [29-33], raw peak areas corresponding to each
peptide were used for peptide quantiﬁcation, and were
calculated from the selected ion chromatograms (SICs)
using Rosetta Elucidator. No normalization/scaling was
performed and peak areas were directly used for Prot-
Pair analysis. A total of 21 patients were investigated using
2 technical replicates from each patient. Thirteen of the
patients developed IPS following the transplants, while
eight patients remained unaﬀected. The outcome under
study was classiﬁcation of the SCT patients into those
who subsequently developed IPS or those who remained
unaﬀected by complications. Protein pairs assigned high
signiﬁcance by ProtPair were imported into Ingenuity
Pathway Analysis (IPA) (Ingenuity Systems, Redwood
City, CA, USA) to uncover protein networks enriched in
the candidate proteins. The software generates networks
based upon biomedical literature and existing protein
interaction databases to reveal biological networks associ-
ated with the candidate proteins.
All patients (or their surrogates) and controls gave writ-
ten, informed consent in accordance with the Declaration
of Helsinki and the trial was approved by the respective
Institutional Review Boards of the University of Michigan
and the Dana-Farber Cancer Center.
Algorithm Description
Consider that the two clinical states to be distinguished
are: patients that progress to a certain disease, called “pro-
gressors” (labeled P); and patients who are unaﬀected by
the disease, called “controls” (labeled C) after a certain
course of time. Let p1, p2, p3,..., pN represent the pep-
tides identiﬁed across all clinical samples. Let ICik and
IPik represent intensities of peptide i obtained from kth
control and kth progressor patient respectively. The inten-
sity values are calculated by integrating the peak area
under the SIC with a 10 ppm window for the corre-
sponding peptide using Rosetta Elucidator, and no pre-
processing/transformation is performed on the peak areas
in order to minimize artifacts that may result from such
processing. All possible pairs of detected peptides are gen-
erated and examined. If there are N number of detected
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relative abundance, the ratio of intensities of peptide pair
(i,j) arising from peptides pi and pj for kth patient for con-








The goal of ProtPair is to ﬁnd a pair of peptides/proteins
that is the most discriminative between the two clinical
conditions of interest. The discriminative power of a pep-
tide pair (i,j) is estimated by its Discriminability Index









and σ symbolize the median and standard
deviation of the input argument, which represent pep-
tide pair intensity ratios for all controls and progressors
as deﬁned in equation 1. The median value for the ratios
indicates the central tendency of the data and is robust in
the presence of outlier values, whereas standard deviation
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measures the variation within the peptide ratio relative
values for the two clinical categories. The discriminability
index is a measure of the distance between the two relative
abundance distributions among the controls versus the
progressors. It describes the inherent and unchangeable
properties arising from the two distributions and hence
assists in selecting the most discriminative features (pep-
tide pairs in this case), and is independent of the decision
strategy employed. Discriminability is increased either by
increasing the separation (numerator) or by decreasing
the spread (denominator) of individual ratio distributions.
The most discriminative peptide pair is determined as
follows:
(m, n) = argmax
i,j
|d(i, j)| (3)
Thus, the peptide pair providing the highest absolute
value of DI among all possibilities is assigned to be the
highest scoring pair.
Each of the peptides is assigned protein identity using
Rosetta Elucidator (Rosetta Biosoftware, Seattle, WA),
peptides that correspond to more than a single protein
in the sequence database are allocated among all corre-
sponding proteins, and a minimal protein list suﬃcient to
account for the observed peptide assignments is derived
using the expectation maximization algorithm [32]. For
further increasing the conﬁdence of protein ID assign-
ment, only proteins identiﬁed with a minimum of 2 high
scoring peptide assignments were considered for candi-
dacy by Protpair. As proteins act as the true molecular
functional units, and are likely to be aﬀected during a dis-
ease, we seek to ﬁnd protein pairs that best classify the
two clinical states. This is done by ﬁrst generating the
list of all possible protein pairs. If there are M number
of proteins detected across all experiments, there will be(M
2
)
protein pairs. The resulting protein pairs are investi-
gated for their ability to consistently diﬀerentiate between
the two clinical states across all possible peptide pairs,
the extent of protein coverage exhibiting the diﬀerential
expression, and consistency in the direction of change to
arrive at the ﬁnal protein pair that leads to the best clas-
siﬁcation. DI for a protein pair P1 and P2 is calculated
as follows:
D(P1,P2) = μ 1
2
(d(i, j)) ∀pi ∈ P1, pj ∈ P2 (4)
Here, ∀ denotes “for all”, and ∈ “belongs to”. For exam-
ple, ∀pi ∈ P1 means - for all the peptides orginating from
protein P1. Thus, the DI factor for proteins P1 and P2 is
deﬁned to be the median value of the DI across all peptide
pairs from proteins P1 and P2. The highest ranked protein
pair is obtained by the following equation:
(m, n) = argmax
i,j
|D(i, j)| (5)
This means that the candidate pair providing the high-
est median value of DI across all peptide possibilities is
assigned to be the top ranked protein pair.
Results and discussion
Results
The overall analysis of mass spectrometry data usingMas-
cot within Rosetta Elucidator framework identiﬁed 1799
peptides resulting from 151 unique proteins across all
patient samples. In order to allow for conﬁdent iden-
tiﬁcation, a false discovery rate of 1% was used as a
threshold for the identiﬁcation of peptides. A total of
112 out of the 151 identiﬁed proteins which were found
to be identiﬁed by at least 2 or more high scoring pep-
tides, were further examined by ProtPair, and the rest
of 39 peptides were excluded from examination. After
eliminating single peptide hits for a protein, 1760 pep-
tides were remaining, which were taken as pairs (leading
to 1547920 unique peptide pairs) in order to determine
their discriminability. The resulting peptide pairs were
further grouped into the corresponding 6216 unique pro-
tein pairs (formed from 112 proteins, taken two at a
time), and the discriminabilty of the pairwise proteins was
investigated.
Table 1 shows the list of protein pairs ranked by their
DI score. If proteins in columns 1 and 2 are denoted by
P1 and P2 respectively, the ratio of intensities of P1:P2 is
higher in the case of IPS progressor patients than that for
controls. This implies that in the case of IPS progressors,
either (a) P1 is upregulated, or (b) P2 is downregulated, or
(c) both (a) and (b) are true. Column 4 denotes the p-value
(probability that a particular score would occur by chance)
associated with each DI score. Since multiple hypothe-
ses (6216) corresponding to each protein pair are being
tested, false discovery rate (FDR) was calculated (Column
5) using empirical null model from permutation tests in
order to correct for multiple hypothesis testing [35-38].
For a speciﬁed DI score threshold, say, T, the number
Strue of observed scores ≥ T and the number Snull of null
scores ≥ T are counted. Assuming that the total num-
ber of observed scores and null scores are equal, then the
estimated FDR is simply SnullStrue .
Figures 1a and 1b show the scatter plot of two unique
peptide pair abundances from top scoring protein pair
(Table 1) APCS (Serum amyloid P-component) [39]
and HGFAC (Hepatocyte growth factor activator) [40],
indicating higher levels of HGFAC in the IPS progressors
(red dots) as opposed to controls (blue dots), while lev-
els of APCS tend to be lower in those cases. Figures 1c
and 1d illustrate the distribution of ratios of inten-
sity signals from two of the most discriminative pep-
tide pairs originating from proteins APCS and HGFAC.
The blue lines indicate the control samples, while red lines
represent the IPS progressors. The solid lines indicate the
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Table 1 Protein pairs ranked by the discriminability index scores
Protein 1 (upregulated in IPS progressors) Protein 2 (downregulated in IPS progressors) DI score p-value FDR rate
APCS Serum amyloid P-component HGFAC Hepatocyte growth factor activator 2.01 0 0.00
C8G Complement component C8 gamma chain HGFAC Hepatocyte growth factor activator 1.60 1.6×10−6 0.01
APCS Serum amyloid P-component CFHR1;LOC100293069 Complement factor H-related 1 1.58 1.6×10−6 0.01
C4BPA C4b-binding protein alpha chain ENO2 Gamma-enolase 1.48 6.3×10−6 0.01
C4BPA C4b-binding protein alpha chain HGFAC Hepatocyte growth factor activator 1.45 9.5×10−6 0.01
APOA4 Apolipoprotein A-IV ALB Putative uncharacterized protein ALB 1.44 9.5×10−6 0.01
APCS Serum amyloid P-component CFHR2 Isoform Short of Complement factor H-related protein 2 1.43 1.1×10−5 0.01
F2 Prothrombin (Fragment) HGFAC Hepatocyte growth factor activator 1.37 3.5×10−5 0.03
APOD Apolipoprotein D HGFAC Hepatocyte growth factor activator 1.35 5.7×10−5 0.05
CPB2 Isoform 1 of Carboxypeptidase B2 HGFAC Hepatocyte growth factor activator 1.31 9.3×10−5 0.08
SERPINA6 Corticosteroid-binding globulin HGFAC Hepatocyte growth factor activator 1.30 9.8×10−5 0.09
APCS Serum amyloid P-component F10 Coagulation factor X 1.30 1.1×10−4 0.09
C8A Complement component C8 alpha chain HGFAC Hepatocyte growth factor activator 1.26 1.6×10−4 0.11
APOA4 Apolipoprotein A-IV GPX3 Glutathione peroxidase 3 1.25 1.7×10−4 0.10
APOB Apolipoprotein B-100 HGFAC Hepatocyte growth factor activator 1.24 1.8×10−4 0.10
FGG Isoform Gamma-B of Fibrinogen gamma chain AZGP1 alpha-2-glycoprotein 1, zinc” 1.23 2.0×10−4 0.10
AGT Angiotensinogen HGFAC Hepatocyte growth factor activator 1.22 2.1×10−4 0.10
APCS Serum amyloid P-component ENO2 Gamma-enolase 1.18 2.8×10−4 0.13
CPB2 Isoform 1 of Carboxypeptidase B2 C1QC Complement C1q subcomponent subunit C 1.17 2.9×10−4 0.12
APCS Serum amyloid P-component GPX3 Glutathione peroxidase 3 1.17 3.0×10−4 0.11
C4BPA C4b-binding protein alpha chain LBP Lipopolysaccharide-binding protein 1.16 3.0×10−4 0.11
APCS Serum amyloid P-component LOC653879 similar to complement component 3 1.15 3.3×10−4 0.11
CPB2 Isoform 1 of Carboxypeptidase B2 AFM Afamin 1.15 3.3×10−4 0.10
true distribution of patients, while the dotted lines are the
best ﬁtting corresponding Gaussian distributions.In both
cases, the measurements independently suggest the over-
all trend that APCS is downregulated while HGFAC is
upregulated in patients that progress to IPS, and is vice-
versa for control samples. The same trend of diﬀerential
expression of proteins is observed across all other peptide
pair possibilities as indicated by their DI values leading to
the highest median value across all protein pairs.
The top scoring protein pair APCS and HGFAC pro-
vided highest discriminability across all peptide pairs,
APCS is an acute phase response protein whose con-
centration is known to change signiﬁcantly in response
to inﬂammation [39,40]. Thus, the data suggests that
patients with dysregulation in the concentration of spe-
ciﬁc acute phase response proteins at the time of bone
marrow transplant are highly likely to develop IPS within
2-3 weeks.
Figures 2a and 2b depict the signiﬁcance of the DI
scores assessed using permutation tests for peptide and
protein pairs respectively. Figure 2a represents null dis-
tribution of the DI for peptide pairs generated using
a total of 100 random permutations of class labels,
while maintaining the original sample size for individ-
ual clinical category. During each permutation, DI score
for all peptide pairs is calculated, and Figure 2a shows
the distribution of DI from all permutations. The true
top peptide score obtained using “true labels” is indi-
cated by black arrow, demonstrating that the probabil-
ity of obtaining the true score from null distribution
is extremely low (p-value< 1.5 × 10−7). Similarly,
Figure 2b represents distribution representing the median
DI of the all protein pairs during 100 permutations,
with arrow indicating the true top DI score using “true
labels”, indicating high statistical signiﬁcance of the true
score (p-value< 10−20). Note that combining multi-
ple peptide pairs from same two protein results in
highly signiﬁcant scores, since its is unlikely that mul-
tiple corresponding peptide pairs show consistent, high
discrimination purely “by chance”, as indicated by the
low p-values and low false discovery rates in Table 1.
Note that the DI scores for most of the peptide and
protein pairs is centered around zero indicating that
no discrimination is being provided by the such pairs.
This is to be expected with permuted labels, since
most proteins/peptides should not exhibit any diﬀerential
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Figure 1 (a) and (b) Scatter plots for two pairs of peptides from top protein pair APCS (Serum amyloid P-component) and HGFAC
(Hepatocyte growth factor activator). The two classes are represented using red and blue, the axes represent the abundance levels of the two
peptides and the black line represents the decision boundary. Peptide sequences of APCS in Figure 1a and 1b: GYVIIKPLVWV, DNELLVYK, while
corresponding sequences for HGFAC: LCNIEPDER and LHKPGVYTR. (c) and (d) Distribution of peptide signal abundance ratios ( APCSHGFAC ) from two
unique peptide pairs originating from proteins APCS and HGFAC. Red and Blue indicate control and IPS progressors respectively.
expression among the arbitrary categories deﬁned by
random labels.
Figure 2c shows the DI scores from constituent peptides
of a randomly picked protein pair (APOH Beta-2-
glycoprotein 1 and FN1 Isoform 1 of Fibronectin), indicat-
ing that the discriminability is close to zero across all pep-
tide pair possibilities. Apolipoprotein H (APOH) is a lipid
binding protein implicated in physiologic pathways for
lipoprotein metabolism, coagulation, and the production
of antiphospholipid autoantibodies, while Fibronectin is
involved in cell adhesion and migration processes includ-
ing embryogenesis, wound healing, blood coagulation,
host defense, andmetastasis. The expression levels of pep-
tide pairs from APOH and Fibronectin do not appear to
aﬀect the prognosis of IPS as indicated by the minimal
discriminability seen in Figure 2c. Figure 2d depicts that
the distribution of DI values of the highest scoring pro-
tein pair (APCS ang HGFAC) is signiﬁcantly shifted to
the right, illustrating that DI scores are consistently and
signiﬁcantly higher for discriminating protein pairs than
their randomly chosen counterparts in Figure 2c.
As described in the Methods section, the proteins from
top 20 pairs were imported into IPA to see if they shared
common biological networks. Figure 3 shows that the
network is associated with respiratory disorders, hema-
tological dysfunction, cardiovascular complications, and
infectious diseases. Figure 4 illustrates the top scoring
network uncovered using IPA software, revealing the
interactions between the top candidate proteins identiﬁed
by ProtPair.
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Figure 2 (a) DI score distribution of peptide pairs with random permutation of class labels, the location of true highest scoring peptide
pair is indicated by arrow (b)Median DI score distribution for protein pairs with randomly assigned class labels, with true top scoring
protein pair shown using arrow (c) DI score distribution from a randomly picked protein pair across all constituent peptides (d) DI score
distribution from the highest scoring protein pair, APCS and HGFAC.
Discussion
A ranking/classiﬁcation methodology for biomarker dis-
covery using pairs of proteins from shotgun mass spec-
trometry based proteomics data has been introduced. The
method leads to concrete hypotheses about the predic-
tive signiﬁcance of speciﬁc protein expression compar-
isons, which can be followed up for future validation. The
method has been explored using clinical proteomics data
from 21 patients (8 controls, 13 disease progressors) dif-
ferentiating between patients progressing to IPS versus
controls that remain unaﬀected by IPS following the bone
marrow transplant procedure. Although sample size of 21
may appear small, it is well accepted an appropriate size
for the discovery and qualiﬁcation phase of development
of biomarker discovery [1].
The initial concept behind ProtPair was inspired by a
rank-based approach for molecular classiﬁcation based
upon pairwise mRNA expression comparisons. Geman et
al introduced top-scoring pair(s) (TSP) classiﬁer for class
prediction in which the mRNA expression levels of genes
are directly compared against each other to each other to
make classiﬁcation [19]. The decision is thus dependent
on only the following question: is the expression of gene
A higher than the expression of gene B in the sample? If
so, the diagnosis is class 1. If the expression of gene B is
higher than for gene A, then the diagnosis is for class 2.
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Figure 3 Ingenuity Pathway Analysis (IPA) analysis: Biological processes and diseases most signiﬁcantly associated with top 20 proteins
identiﬁed by ProtPair.
Such decision rules implicitly draw the decision bound-
ary line at y = x. Although this approach has been highly
successful for mRNA expression experiments, our initial
attempts to directly adopt this method were unsuccess-
ful. Since peptides signals exhibit a wide dynamic range,
we needed a more general approach than y = x boundary
line used in mRNA studies. For example, Figure 5 shows
a scenario where the two disease classes (represented by
red and blue) are clearly separable, but y = x boundary
line is not an optimal separation line. Thus, we propose a
more general scheme without any implicit normalization
assumtions.
Figures 1a and 1b show the scatter plots of pep-
tide intensities from the top scoring proteins APCS and
HGFAC. Note that as in the case of single protein/peptide
markers, none of the proteins/peptides is able to pro-
vide good separation between the two categories by itself.
The best way of discriminating among the two cases is
by drawing a line (black, separation boundary) that is
close to the “diagonal” line (suggesting that both can-
didates contribute towards discrimination), instead of
being closer to a horizontal or a vertical line (indicating
that the separation could be provided by a single pro-
tein). Hence, the combination of pairwise markers gains
strength by combining the discrimination power achieved
by both markers, which is not possible by treating pep-
tide/protein markers in isolation, as is often done in the
traditional analysis. When all constituent peptide pairs
from two proteins exhibit consistent trend of signiﬁcant
diﬀerential expression change, all corresponding DI index
values increase, leading to a high median DI index value
across the protein pair.
The signiﬁcance of the score was assessed using per-
mutation analysis. Artiﬁcial data set was constructed by
randomly rearranging class labels, while maintaining the
original sample sizes of 8 and 13 for controls and IPS pro-
gressors respectively. The resulting scores mirror those
obtained by pure chance without any meaningful biolog-
ical signiﬁcance, while maintaining the overall statistical
dependency structure among peptides/proteins. Figure 2a
displays the distribution of peptide pair scores obtained
from 100 permutations. From this null distribution, a p-
value associated with a given score from unpermuted
“true” data can be computed by taking the fraction of
permuted data sets in which a score of at least as large
is obtained. This p-value is a measure of probability of
observing a given score under the null hypothesis that the
pairs are non informative for classiﬁcation. Only 23 among
the 154792000 (100 permutations, with 1547920 peptide
pair scores in each permutation) scores came greater than
or equal to the actual top score, yielding a p-value of
1.5 × 10−7. Similarly, Figure 2b shows the distribution of
top scores obtained using 100 permutations from protein
pairs by taking the median of all constituting peptides. No
score from 6216 protein pairs among the 100 permuta-
tions came near the true top score (marked by arrow in
Figure 2b), yielding a p-value of virtually 0. The method
gains signiﬁcant strength by combining multiple peptide
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Figure 4 Top scoring biological network obtained using IPA analysis representing cluster of highly signiﬁcant proteins identiﬁed by
ProtPair.
pairs originating from the same set of proteins, since each
unique peptide pair provides an independent measure of
discriminatory power, which is unlikely to arrive by pure
chance alone.
The expected generalization error rate of ProtPair for
the IPS data set was performed using leave-one-out cross
validation (CV). This involves using both technical repli-
cates from a single patient as the test data, and the remain-
ing samples as the training data, and is repeated such that
samples from each patient is used exactly once as the test
data. Note that in order to obtain an unbiased validation,
leave one out cross validation study refers to each patient
as opposed to each measurement, and all measurements
from a single patient were left out during each training
step. In particular, both the actual top scoring DI value,
as well as the set of pairs which achieve it, can vary with
the sample left out. The estimated prediction rate is 1− eN
where e is the number of misclassiﬁcations observed on
the test data during the cross-validation, and N (42 for
the case of IPS study) being the total number of sam-
ples. For this procedure, there is only a single parameter,
threshold of peptide abundance ratios, to select inside the
cross validation loop. For other procedures that do require
multiple parameters, such as k-nearest neighbors, ran-
dom forests and support vector machines, the estimated
prediction rates may be highly biased if performance is
sensitive to these parameters and they are not properly
cross-validated. The prediction rate of the ProtPair for IPS
study as measured by leave-one-out CV is 69.1% (corre-
sponding to 13 errors across 42 samples). This is less than
Kaur et al. BMC Bioinformatics 2012, 13:191 Page 10 of 13
http://www.biomedcentral.com/1471-2105/13/191
Figure 5Most discriminating feature pair based uponMS1 only features.
the 78% error rate seen in Figure 1, but is not unreason-
able. In fact, a 70% prediction rate may be highly beneﬁcial
for clinical diagnosis as it may ﬂag patients in need ofmore
frequent monitoring. In addition, the results obtained are
consistent with recent studies by more conventional sta-
tistical methods [28]. This biomarker prediction is based
on data from the day of SCT, the indicated biomarkers
may be altered further during progression to IPS. Note
also that the CV accuracy of a classiﬁer is highly depen-
dent upon the biological complexity of a given disease,
sample size and population diversity, and heterogeneity
of the underlying phenomenon. In addition, the highest
scoring pair may change when the training data is even
slightly perturbed by adding or deleting a few samples so
that the CV accuracy is not necessarily reﬂective of global
accuracy provided by the ultimate ﬁnal pair (HGFAC and
APCS in this case). As seen in Figure 1, although there is
some amount of overlap, the ﬁnal protein pair consistently
shows strong evidence of discrimination among the two
patient populations, illustrating the emergent behavior of
protein expression change across the two populations. In
addition to being a classiﬁer, ProtPair has high utility as
a predictive and actionable tool to rank proteins in the
order of discrimination providing candidates for future
validation testing speciﬁc hypotheses.
To understand if the totality of the expressed protein
list is consistent with known pathways of IPS, we used
Ingenuity Pathway Analysis (IPA) to explore dysregulated
pathways suggested by the proteins seen to be signiﬁ-
cantly changing. As described in the Methods section, the
top 20 proteins were imported into IPA. IPA has several
algorithms to identify if the set of proteins imported are
associated with speciﬁc “canonical” pathways or biologi-
cal processes and diseases. Nodes within the network are
displayed using various shapes that represent the func-
tional class of the protein. All edges are supported by
at least one reference from the literature, from a text-
book, or from canonical information stored in the Inge-
nuity Knowledge Base. In terms of processes and diseases
(Figure 3), the imported protein set was most signiﬁcantly
associated with the following: respiratory disease, cell to
cell signaling and interaction, tissue development, cardio-
vascular disease, and hematological disease (all with p
values < 10−6). Inﬂammatory diseases and inﬂammatory
response were also highly signiﬁcant (p values = 10−5).
In terms of canonical processes, acute phase response
was top ranked (data not shown, p value < 10−7). These
results are quite encouraging and validate the method as
ProtPair “top ranked” proteins are associated with the
biological processes and pathways intimately associated
with known IPS biology based on both mouse models
and human studies, such as respiratory disease, inﬂam-
matory responses, and acute phase response [41-45].
These pathway dysregulations are consistent with recent
studies [28].
In order to more speciﬁcally examine the dysregulated
protein networks suggested by the top 20 proteins, we
used the IPA database to create a dense sub-network
of targets, where the dysregulated proteins (nodes) are
shaded and IPA inserts additional nodes (colored white)
and annotated interactions (edges) in order to connect as
many of the targets as possible while restricting the total
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number of nodes added (Figure 4). For example, Prot-
Pair identiﬁed lipopolysaccharide binding protein (LBP),
Fibrinogen, Hepatocyte growth factor activator (HGFAC,
a top scoring protein), ﬁbrinogen gamma chain (FGG),
coagulation factor X (F10), and thrombin (F2) as chang-
ing in case versus control samples. The changes seen
for LBP have been recently conﬁrmed by ELISA stud-
ies [28]. IPA inserted extracellular-signal-regulated kinase
(ERK1/2) and nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-KB) as they have direct con-
nections (e.g. annotations of binding or regulatory con-
trol) associated with those proteins. This is consistent
with the overall dysregulatory themes of acute phase
response and cell-cell signaling as NF-KB is transcrip-
tion factor controlling expression for many acute phase
response proteins and is regulated by TNF-α, which is
a target for IPS therapies in clinical trials [43-46] while
ERK1/2 proteins (also termed MAP kinases) regulate
cell growth.
In its present form, ProtPair makes predictions based
entirely on the top scoring pairs. In the case of IPS study,
there is in fact a unique top scoring pair - HGFAC and
APCS, which appears to have biological interest. However,
there may be many other pairs whose relative expression
values are informative. One possible direction of future
work is to ﬁnd a more stable, comparison-based signature
combining multiple high scoring pairs. For example, one
may envision a ProtPair classiﬁcation based on all pro-
tein pairs achieving the k best scores. In this case, k is
a parameter whose optimal value can be estimated using
cross-validation.
An alternative discovery based approach to using Prot-
Pair would be to use it to detect variation in abundance
patterns in comprehensive peptide lists, irrespective of
their annotation status. For example, Rosetta Elucida-
tor framework was used to extract raw peak areas from
SICs corresponding to all of the 11108 isotopic features
observed inMS1, regardless of the presence/annotation of
the tandem MS spectrum for the feature. Note that conﬁ-
dent annotationMS/MS is available for only 1799 peptides
of the overall 11108 features. Using pairwise comparison
of these comprehensive list of global features led to the
best discriminating feature pair shown in Figure 5, where
the 2 axesmark the abundances of individual features. The
ﬁgure reveals a clear separation between the 2 groups as
deﬁned by the feature intensities. Due to the low signal
intensity of such features, it is likely that they are typically
either not selected for tandem MS or had extremely low
signal in the tandemMS leading to missed/low conﬁdence
assignment. However, the MS1 data could be used in an
alternative targetedMS approach, which is specially useful
to target low abundance but important proteins/peptides
that may experience a negative bias towards selection dur-
ing the tandem MS sampling. Such integration between
experimental and computational workﬂows can be very
valuable for targeted MS in the future.
The results already provide evidence that discriminat-
ing comparisons among protein expression levels can be
discovered even under conditions of small sample size.
Given the large number of variables (peptides/proteins), a
patient population sample size of 21 is considered small.
With number of samples in the order of hundreds, more
complex decision trees can be learned from the data, using
only comparison questions, thus maintaining easily inter-
pretable results that do not require any normalization.
The corresponding decision rules would then be based
onmore complex peptide abundance comparisons involv-
ing more than two proteins. The methodology can also be
extended to more complex and heterogeneous data sets,
for example those combined from samples obtained from
various sources such as plasma, urine, or organ speciﬁc
tissue as well as other MS variables that reﬂect intensity,
such as spectral counts. With small amounts of data, it
may only be possible to collect reliable estimates of pair-
wise comparisons among expression levels so as to avoid
overﬁtting. More data could be used to model the statisti-
cal dependency structure among families of proteins such
as metabolic and regulatory pathways etc. This approach
lends itself to a natural, hierarchical family of mod-
els which can accommodate various kinds and amounts
of data.
Conclusions
Amethodology tomolecular classiﬁcation for disease pro-
gression using pairs of peptides/proteins from shotgun
mass spectrometry based proteomics data has been pre-
sented. The strength of this linear approach lies in its
design for being able to handle high dimensional data with
small sample size by (i) using minimal number of features
in order to avoid over ﬁtting of the data (ii) observing
consistency of diﬀerential expression change across two
disease conditions (iii) aggregating peptide pairs origi-
nating from the same pair of proteins to classify at the
level of protein pairs through joint statistics. Since pro-
teins act as the true functional machines in an organism,
predictions based upon ratios of protein expression levels
provide a natural link with biological phenomenon. The
method has been tested using clinical proteomics data
from 21 patients following a bone marrow transplant, dif-
ferentiating between 13 patients progressing to IPS versus
8 controls that remain unaﬀected by IPS. The approach
gains power by combining multiple peptide pairs origi-
nating from the same set of proteins, with each unique
peptide pair providing an independent measure of dis-
criminatory power. The prediction rate of the ProtPair
for IPS study as measured by leave-one-out CV is 69.1%,
which may be very beneﬁcial for clinical diagnosis as it
may ﬂag patients in need of more frequent monitoring.
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It was encouraging to ﬁnd that the “top ranked” proteins
provided by ProtPair are known to be associated with the
biological processes and pathways intimately associated
with known IPS biology based on both mouse models,
such as respiratory disease, inﬂammatory responses, and
acute phase response. Proteins from top 20 pairs were
imported into IPA to see if they shared common biological
networks. The network was found to be enriched in acute
phase response proteins whose concentration is known
to change signiﬁcantly in response to inﬂammation, and
is associated with respiratory disorders, hematological
dysfunction, cardiovascular complications, and infectious
diseases. The data indicates that patients with improper
regulation in the concentration of speciﬁc acute phase
response proteins at the time of bone marrow transplant
are highly likely to develop IPS within few weeks. The
results lead to a speciﬁc set of protein pairs that can be
eﬃciently veriﬁed by investigating the pairwise abundance
change in independent cohorts using ELISA or targeted
mass spectrometry techniques.
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